Gossamer Bio

GOSS

Market cap $501M

- Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH and PH-ILD - PALO ALTO, Calif. , Sept. 25, 2025 /PRNewswire/ -- Respira Therapeutics, Inc. (Respira or the "Company"), a Samsara BioCapital portfolio company, today announced that it has entered into an agreement with Gossamer Bio, Inc. (Gossamer) (Nasdaq: GOSS) granting Gossamer an option to acquire the Company.

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced it has entered into an option agreement to acquire Respira Therapeutics (Respira) and its lead product candidate, RT234, an investigational inhaled vardenafil dry‑powder.

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that five scientific presentations related to seralutinib will be presented at the European Respiratory Society (ERS) Congress 2025, which takes place from September 27th thro.

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective September 5th, 2025, to two non-executive employees of non-qualified stock.

GOSS's Seralutinib remains its main value driver. This is an inhaled TKI for PAH and PH-ILD. Seralutinib's PROSERA Phase 3 trial is now fully enrolled with 6MWD as its primary endpoint. We should get its topline data by February 2026. As for Seralutinib's PH-ILD indication, the SERANATA Phase 3 trial will begin site activations in Q4 2025.

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the following investor conferences in September. Cantor Global Healthcare Conference   Date / Time: September 3rd, at 9:10 AM ET Format:.

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective August 5th, 2025, to three non-executive employees of non-qualified stock.

Gossamer Bio (GOSS) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to earnings of $0.22 per share a year ago.

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the second quarter ended June 30, 2025, and provided a business update. Gossamer Bio and the Chiesi Group are jointly developing seralutinib un.

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced enrollment completion for the ongoing, global registrational Phase 3 PROSERA Study evaluating seralutinib in Functional Class II and III PAH patients. Gossamer Bio and t.